This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mononen, N. Articles by Koivisto, P. A. Search for Related Content PubMed PubMed Citation Articles by Mononen, N. Articles by Koivisto, P. A.

Two Percent of Finnish Prostate Cancer Patients Have a Germ-line Mutation in the Hormone-binding Domain of the Androgen Receptor Gene¹

Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital [N. M., K. S., M. M., J. S., O-P. K., P. A. K.]; Department of Clinical Genetics, Tampere University Hospital [P. A. K.]; and Division of Urology, Tampere University Hospital and Medical School, University of Tampere [T. L. J. T.], 33521 Tampere, Finland; Laboratory of Cancer Genetics, National Center for Human Genome Research, NIH, Bethesda, Maryland 20892-4470 [J. S., O-P. K.]; and Department of Pathology, Erasmus University, 3000 Rotterdam, the Netherlands [J. T.]

Mutations of the androgen receptor (AR) gene have been reported in prostate cancer, usually from tumor tissue specimens from late-stage, androgen-independent cancer. Occasionally, germ-line mutations have been found, but a link between AR mutations and predisposition to human prostate cancer has not been firmly established. Recently, two independent studies reported the same germ-line mutation at codon 726 in exon E (CGC to CTC) in two apparently unrelated Finnish prostate cancer patients. This arginine to leucine substitution was reported to alter the transactivational specificity of the AR protein. In the present study, the R726L mutation was analyzed by allele-specific oligohybridization in DNA specimens from 418 consecutive prostate cancer patients who reported a negative family history (sporadic group) and from 106 patients with a positive family history (hereditary group). The population frequency of the R726L mutation in blood donors was 3 of 900 (0.33%). In contrast, eight (1.91%) mutations (odds ratio = 5.8; P = 0.006) were found in the sporadic group, and two (1.89%) mutations were found in the hereditary group (odds ratio = 5.8; P = 0.09). Suggestive evidence of the segregation of the mutation with prostate cancer was seen in these two families. The present study indicates that the R726L substitution in the AR may confer an up to 6-fold increased risk of prostate cancer and may contribute to cancer development in up to 2% of Finnish prostate cancer patients. These results warrant additional large-scale studies of the significance of rare mutations and polymorphisms in candidate genes along the androgen signaling pathway as risk factors for prostate cancer.

This article has been cited by other articles:

				X. Wang, F. Wang, K. Taniguchi, R. S. Seelan, L. Wang, K. E. Zarfas, S. K. McDonnell, C. Qian, K. Pan, Y. Lu, et al. Truncating Variants in p53AIP1 Disrupting DNA Damage-Induced Apoptosis Are Associated with Prostate Cancer Risk Cancer Res., November 1, 2006; 66(21): 10302 - 10307. [Abstract] [Full Text] [PDF]

				B. He, R. T. Gampe Jr., A. T. Hnat, J. L. Faggart, J. T. Minges, F. S. French, and E. M. Wilson Probing the Functional Link between Androgen Receptor Coactivator and Ligand-binding Sites in Prostate Cancer and Androgen Insensitivity J. Biol. Chem., March 10, 2006; 281(10): 6648 - 6663. [Abstract] [Full Text] [PDF]

				N. Mononen, E. H. Seppala, P. Duggal, V. Autio, T. Ikonen, P. Ellonen, J. Saharinen, J. Saarela, M. Vihinen, T. L.J. Tammela, et al. Profiling Genetic Variation along the Androgen Biosynthesis and Metabolism Pathways Implicates Several Single Nucleotide Polymorphisms and Their Combinations as Prostate Cancer Risk Factors Cancer Res., January 15, 2006; 66(2): 743 - 747. [Abstract] [Full Text] [PDF]

				C. A. Heinlein and C. Chang Androgen Receptor in Prostate Cancer Endocr. Rev., April 1, 2004; 25(2): 276 - 308. [Abstract] [Full Text] [PDF]

				E. P. Gelmann Molecular Biology of the Androgen Receptor J. Clin. Oncol., July 1, 2002; 20(13): 3001 - 3015. [Abstract] [Full Text] [PDF]

				A. Rokman, T. Ikonen, N. Mononen, V. Autio, M. P. Matikainen, P. A. Koivisto, T. L. J. Tammela, O.-P. Kallioniemi, and J. Schleutker ELAC2/HPC2 Involvement in Hereditary and Sporadic Prostate Cancer Cancer Res., August 1, 2001; 61(16): 6038 - 6041. [Abstract] [Full Text] [PDF]

				J. Thompson, F. Saatcioglu, O. A. Janne, and J. J. Palvimo Disrupted Amino- and Carboxyl-Terminal Interactions of the Androgen Receptor Are Linked to Androgen Insensitivity Mol. Endocrinol., June 1, 2001; 15(6): 923 - 935. [Abstract] [Full Text] [PDF]